How many &to=http://english.pravda.ru/society/2002/07/12/32330.html' target=_blank>drugs already are on the market without having been evaluated adequately for safety?
Last week, Sen. Charles Grassley, R-Iowa, chairman of the Senate Finance Committee, called for an independent federal panel, similar to the 9/11 Commission, to investigate drug safety. It was recognition, far too long in coming, that things have gone terribly wrong at the Food and Drug Administration.
Millions of Americans have paied more for a new arthritis drug that's no better at relieving pain than dozens of other drugs already on the market. Thanks to them, a class of pain relievers called COX-2 inhibitors - Pfizer's Celebrex and Bextra, and Merck's Vioxx - have become blockbusters. Celebrex is expected to bring in $3.3 billion this year. Vioxx accounted for $2.5 billion in sales last year.
An objective analysis of where the United Kingdom and its Prime Minister stand one hundred days before the Brexit deadline. Let us see the facts, not conjecture